Cytochrome P450 2E1 RsaI/PstI and DraI Polymorphisms Are Risk Factors for Lung Cancer in Mongolian and Han Population in Inner Mongolia

被引:0
|
作者
Xiu-lan Su1**
2Department of Internal Medicine
机构
关键词
Cytochrome p450 2E1; Gene polymorphism; Lung cancer; Susceptivity;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
Objective: To explore the relationship between cytochrome P450 2E1 (CYP2E1) RsaI/PstI and DraI polymorphism and lung cancer susceptibility in Mongolian and Han population in Inner Mongolia of China. Methods: CYP2E1 RsaI/PstI and DraI polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism in 64 lung cancer patients, 150 healthy Mongolian and 150 healthy Han individuals. The distribution of genotype and allele frequencies of CYP2E1 RsaI/PstI and DraI polymorphisms were studied. Results: The risk of lung cancer was increased in individuals with CYP2E1 (cl/cl) and CYP2E1 (DD) with OR values of 2.431 (95%CI=1.082-5.460) and 2.778 (95%CI=1.358-5.683) respectively (P<0.05). When CYP2E1 RsaI/PstI and DraI polymorphisms were combined, the risk of lung cancer was reduced in individuals with CYP2E1 (cl/c2+c2/c2 and DD+CC) with OR values of 0.233 (95%CI=0.088-0.615, P<0.05). In smokers, the susceptibility to lung cancer was higher in the individuals with CYP2E1 (c1/c1) and CYP2E1 (DD) than in the individuals with c2 and C allele (P<0.05, OR=2.643 and 4.308 respectively). There was no significant difference in distribution of CYP2E1 genotype frequency between healthy Mongolian, Han population and lung cancer patients, healthy controls in Inner Mongolia. Conclusion: CYP2E1 (c1/c1) and CYP2E1 (DD) are predisposing factors of lung cancer in population in Inner Mongolia. CYP2E1 (c2﹢C) co-mutation may decrease the risk of lung cancer. Smoking exerts synergetic effect with CYP2E1 (c1/c1) and CYP2E1 (DD) on the occurrence of lung cancer.
引用
收藏
页码:107 / 111
页数:5
相关论文
共 50 条
  • [31] Inactivation of cytochrome P450 2E1 by tert-butylisothiocyanate
    Kent, UM
    Roberts, ES
    Chun, J
    Hodge, K
    Juncaj, J
    Hollenberg, PF
    CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (10) : 1154 - 1161
  • [32] Homology modeling of cytochrome P450 2E1 enzyme.
    Tropsha, A
    Waller, CL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 84 - COMP
  • [33] Cytochrome P450 2E1: its clinical and toxicological role
    Tanaka, E
    Terada, M
    Misawa, S
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2000, 25 (03) : 165 - 175
  • [34] Cytochrome P450 2E1 activity in diabetic and obese patients
    Lucas, D
    Farez, C
    Attali, JR
    Menez, JF
    Valensi, P
    DIABETOLOGIA, 1997, 40 : 1559 - 1559
  • [35] Updated Meta-analysis of the Association Between CYP2E1 RsaI/PstI Polymorphisms and Lung Cancer Risk in Chinese Population
    Wang, Ya-Dong
    Yang, Hai-Yan
    Liu, Jing
    Wang, Hai-Yu
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (13) : 5411 - 5416
  • [36] Direct electrochemistry of immobilized human cytochrome P450 2E1
    Fantuzzi, A
    Fairhead, M
    Gilardi, G
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (16) : 5040 - 5041
  • [37] Measurement of immunoreactive cytochrome P450 2E1 in human leucocytes
    Scobbie, AE
    Mason, HJ
    BIOMARKERS, 1999, 4 (04) : 311 - 317
  • [38] Differential effects of naturally occurring isothiocyanates on the activities of cytochrome P450 2E1 and the mutant P450 2E1 T303A
    Moreno, RL
    Goosen, T
    Kent, UM
    Chung, FL
    Hollenberg, PF
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 391 (01) : 99 - 110
  • [39] Active site topology of human cytochrome P450 2E1
    Mackman, R
    Guo, ZY
    Guengerich, FP
    OrtizdeMontellano, PR
    CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (01) : 223 - 226
  • [40] Minipig cytochrome P450 2E1:: Comparison with human enzyme
    Baranová, J
    Anzenbacherová, E
    Anzenbacher, P
    Soucek, P
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) : 862 - 865